Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wedbush

Keros Therapeutics (NASDAQ:KROS) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Friday, MarketBeat reports. They presently have a $15.00 price target on the stock, down from their previous price target of $47.00. Wedbush’s target price suggests a potential upside of 38.12% from the stock’s previous close.

Several other research firms have also recently commented on KROS. Wells Fargo & Company increased their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. HC Wainwright dropped their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $10.86 on Friday. The company has a 50-day simple moving average of $36.37 and a two-hundred day simple moving average of $47.13. The stock has a market capitalization of $439.94 million, a PE ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million during the quarter. During the same period in the prior year, the firm posted ($1.33) EPS. The firm’s revenue was up 4750.0% compared to the same quarter last year. As a group, equities research analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV increased its position in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics during the 3rd quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics during the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics during the 3rd quarter worth approximately $213,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.